Articles from Virta Health

Virta Health, the leader in reversing metabolic disease, today announced new peer-reviewed research published in Endocrine Research demonstrating that its nutrition-based metabolic care model delivers broad and sustained reductions in inflammatory markers in adults with type 2 diabetes (T2D). In the study, 19 of 21 inflammatory and immune markers significantly improved after one year of treatment, with improvements largely maintained through two years. This nutrition-based therapy demonstrated broad anti-inflammatory effects across multiple markers, without the known risks of serious side effects associated with some medications. No currently FDA-approved medication targets such a broad spectrum of inflammatory markers.

Virta Health, the leader in reversing metabolic disease, announced today results from a randomized, controlled Phase II clinical trial (RCT), offering an early signal that could reshape how advanced pancreatic cancer is treated. Conducted in partnership with USC Norris Comprehensive Cancer Center, Mayo Clinic, HonorHealth Research Institute, and others, the study was peer-reviewed and published in Cancer, revealing that Virta’s medically supervised, individualized nutrition therapy—long proven effective in reversing metabolic diseases like type 2 diabetes and obesity—also shows promise in extending survival in patients with metastatic pancreatic cancer when used alongside chemotherapy.

Virta Health, the leader in reversing metabolic disease, has released its inaugural Annual Report on Metabolic Disease Reversal. The report underscores a fundamental truth: the most powerful way to revolutionize healthcare and lower costs is not through disease management, but disease reversal, at scale.

Virta Health today announced it has surpassed $160 million in annualized revenue, marking a major milestone in its mission to reverse metabolic disease through a nutrition-first approach. With more than 80% year-over-year revenue growth, significant rise in membership, and improving profitability, Virta is one of digital health’s fastest-scaling companies, uniquely positioned to address the root cause of metabolic disease and offer sustainable alternatives to GLP-1 medications.

Virta Health, a leader in sustainable weight loss and diabetes reversal, announced today its selection by the Centers for Medicare & Medicaid Services (CMS) to join the newly launched Health Tech Ecosystem Initiative. As one of a small group of trusted early adopters, Virta is proud to help lead a new era of digital innovation and interoperability to better serve Americans living with chronic diseases like obesity and diabetes, particularly those on Medicare.

Virta Health, a leader in diabetes reversal and sustainable weight loss with a nutrition-first approach, announced today that Laura Walmsley has been appointed Chief Commercial Officer. A seasoned executive with over 25 years of experience driving transformational growth in healthcare, Walmsley joins Virta to lead its commercial strategy, including enterprise partnerships and all client-facing teams.

Virta Health, a leader in diabetes reversal and sustainable weight loss with a nutrition-first approach, today released a report showing that people can maintain weight loss after stopping GLP-1 medication with the right guidance and lifestyle support—challenging the belief that weight regain is inevitable. Critically, the survey found those who tapered off GLP-1s under medical guidance were eight times more likely to continue losing weight after stopping (56%), compared to the 7% who quit abruptly.

Virta Health, a clinical leader in sustainable weight loss and diabetes reversal through a nutrition-first approach, today announced industry-first cost guarantees for weight loss. The guarantees eliminate financial risk for employers and health plans by ensuring Virta’s weight loss program pays for itself and reining in GLP-1 spending increases, which are rising 70–200% annually across the industry. Virta now commits to stopping these increases completely, delivering 0% GLP-1 utilization growth for employers offering this drug class for obesity, while also guaranteeing strong weight loss outcomes1.

Virta Health, a leader in diabetes reversal and sustainable weight loss with a nutrition-first approach, announced early and compelling results from its Sustainable Weight Loss GLP-1 prescribing capabilities, launched earlier this year. The outcomes highlight a revolutionary shift in obesity and weight loss care, offering organizations a responsible way to cover GLP-1s for weight loss, while reducing reliance and curbing total costs for the medications.

Virta Health, the leader in diabetes reversal and sustainable weight loss with a nutrition-first approach, announced record and accelerating growth of more than 60% year-over-year, at a scale of more than $100 million in annualized revenue. Driven by demand for its Sustainable Weight Loss (SWL) solution—now expanded to include ‘Responsible Prescribing’ capabilities—and continued growth of its diabetes reversal offering, Virta works with more than 550 organizations and covers over 12 million U.S. lives.

Virta Health has released first-of-its-kind, peer-reviewed data demonstrating the company’s approach to personalized nutrition therapy results in sustained weight loss after the discontinuation of glucagon-like peptide-1 receptor agonists (GLP-1s), including Ozempic. Published today in Diabetes Therapy, the data demonstrates Virta is a powerful and sustainable off-ramp from GLP-1s.

Virta Health, the leader in drug-free clinical weight loss and type 2 diabetes reversal, today announced significant traction against the company’s expansion into weight loss solutions. In late 2020, Virta expanded its offerings beyond type 2 diabetes to additional clinical indications, including people living with prediabetes and obesity. Virta announced it recently started treating overweight individuals with a BMI of 25 and above, further demonstrating the reach, effectiveness, and cost reduction potential of a non-pharmaceutical approach to clinical weight loss.

Virta Health, the leader in type 2 diabetes reversal, released real-world data at the American Diabetes Association’s 83rd Scientific Sessions demonstrating how its approach is narrowing gaps in care. The research highlights Virta’s impact on health equity, showing significant health improvement and medication reduction for members living across the most and least disadvantaged neighborhoods in the U.S.

Type 2 diabetes reversal leader Virta Health reported substantial growth of its obesity solution over the last three years. Today, the company partners with more than 70 employers and insurers—such as U-Haul and Quartz—that offer Virta’s provider-led weight loss solution in addition to diabetes reversal.

Virta Health, the leader in type 2 diabetes reversal, is expanding its C-suite as the company scales to meet heightened demand for its chronic disease reversal solutions.

Type 2 diabetes reversal leader Virta Health and U-Haul International, Inc. announced 90-day outcomes from their partnership, including blood sugar reduction, weight loss, and medication deprescription for participating U-Haul Team Members.

Today, Virta Health, the type 2 diabetes reversal leader, announced two-year patient outcomes from its multi-year partnership with the Department of Veterans Affairs (VA). The results, presented at the American Diabetes Association 82nd Scientific Sessions, highlight broad metabolic health improvements for Veteran patients, including long-term blood sugar reduction, clinically-significant weight loss, and medication deprescription.

Virta Health, the leader in type 2 diabetes reversal, revealed preliminary five-year results from its landmark clinical trial at the American Diabetes Association 82nd Scientific Sessions. Presenting four unique abstracts, Virta highlighted myriad, lasting health improvements for people with type 2 diabetes and prediabetes, including blood sugar control, clinically-significant weight loss, reduced inflammation, and improvements in other markers of cardiometabolic health.

Today, diabetes reversal leader Virta Health announced the addition of Shane Henderson as Chief Technology Officer (CTO). With over three decades of experience at companies like Signify Health and Match.com, Shane joins to scale Virta’s technology through continued triple-digit growth and surging demand for its innovative approach to treating metabolic diseases like type 2 diabetes, prediabetes, and obesity.

Please replace the graphic with the accompanying corrected graphic.

Virta Health, the leader in type 2 diabetes reversal, earned the Validation Institute’s most prominent, Level 1 savings validation for delivering unmatched medication cost reductions. Per the analysis, Virta’s validated prescription drug savings amounted to nearly $6k per patient over a two-year period.

Virta Health, the leader in type 2 diabetes reversal, announced promising results on the impact of its diabetes reversal treatment on depressive symptoms. The research, published in The Journal of Behavioral Medicine, highlights rapid and sustained improvement in depressive symptoms during treatment, with nearly one-third fewer patients meeting the clinical cutoff for depression at two years.

Today Virta Health, the leader in type 2 diabetes reversal, announced it now works with more than 20 national and regional health plans, marking 133% year-over-year growth with large insurer customers. Of these partners, nearly half—including Humana and Providence Health Plan—now offer Virta’s diabetes reversal treatment to their self-funded employer groups, representing thousands of companies and over 5M covered lives.

Virta Health, the type 2 diabetes reversal leader, announced a series of senior leadership appointments aimed at expanding the reach of its virtual metabolic clinic and taking diabetes reversal mainstream.

Virta Health, the leader in type 2 diabetes reversal, saves payers $425 per patient per month (PPPM)—more than $10k over two years—according to a new internal analysis. The study, which is based on a methodology validated by independent actuarial firm Milliman, Inc., affirms Virta’s financial impact on employers, health plans, and patients struggling with the out-of-control costs of diabetes care.

Virta Health’s two-day Moonshots for Health conference—launching Wednesday, September 8—brings together dozens of industry leaders to discuss big ideas for reversing America’s chronic disease epidemic and improving healthcare across the globe.

Virta Health, the leader in type 2 diabetes reversal, today announced promising results on the ability of its treatment to mitigate COVID-19 severity. Presenting abstract data at the American Diabetes Association 2021 Scientific Sessions, the company highlighted low rates of hospitalization, ventilation, and mortality for Virta patients living with type 2 diabetes who also contracted COVID-19.

Virta Health, the type 2 diabetes reversal leader, today announced several additions to its executive team, including the appointment of Cybele Bjorklund as Senior Vice President (SVP) of Policy and Government Affairs. Accompanying Bjorklund’s hire are the promotions of Divya Bhat to Chief Product Officer and Amit Shah to Chief Clinical Operations Officer.

Today, Virta Health, the type 2 diabetes reversal leader, announced one-year patient outcomes from its multi-year partnership with Mashantucket Pequot Tribal Nation, with promising results in A1c reduction, weight loss, and insulin de-prescription. Notably, at one year of the Virta Treatment, Pequot patients reduced their insulin prescriptions by 78%. These outcomes also drove significant cost savings—at two years, the tribe’s spend on diabetes-specific medications decreased by 72%.

Virta Health, the leader in type 2 diabetes reversal, today announced $133 million of equity financing led by Tiger Global. The latest funding round will accelerate Virta's efforts to drive widespread adoption of its telehealth-powered diabetes reversal treatment. Virta helps people reverse their chronic disease while removing the need for costly medications, including insulin.